Abstract
The non-steroidal anti-inflammatory drug phenylbutazone is known to have a number of adverse side effects, however, its use in the equine remains widespread. To protect the human consumer, an action level of 50 ng mL−1 in plasma has been agreed by the European Union and regulatory compliance requires a methodology validated to the EU guidelines SANCO/1805/200 revision 6. Accordingly, a GC-MS method has been developed and validated to serve this purpose. The method counters the adverse effects of strong protein binding and the instability of phenylbutazone at low pH. Selected ion monitoring (SIM) allows the acquisition of three diagnostic ions and the use of a deuterated internal standard secures good quantitative performance.
Similar content being viewed by others
References
Gowik P, Julicher B, Uhlig S (1998) J Chromatogr B 716:221–232
Marunaka T, Shibata T, Minami Y, Umeno Y (1980) J Chromatogr 183:331–338
Martin K, Stridsberg M, Wiese B (1983) J Chromatogr 276:224–229
Caturla M, Cusido E (1992) J Chromatogr 581:101–107
Gupta R (1990) J Chromatogr 530:160–163
Singh A, Jang Y, Mishra U, Granley K (1991) J Chromatogr 568(2):351–361
Lai C, Moore P, Quon C (1995) Res Commun Mol Pathol Pharmacol 88(1):51–62
Youden WJ, Steiner EH (1975) In: Statistical Manual of the Association of Official Analytical Chemists, AOAC-I, Washington DC: p35ff
Author information
Authors and Affiliations
Corresponding author
Additional information
In Honour of Professor Edward Houghton: A Celebration of 30 Years in Racing Chemisty
Rights and permissions
About this article
Cite this article
Hines, S., Pearce, C., Bright, J. et al. Development and Validation of a Quantitative Gas Chromatography – Mass Spectrometry Confirmatory Method for Phenylbutazone in Equine Plasma. Chromatographia 59 (Suppl 1), S109–S114 (2004). https://doi.org/10.1365/s10337-004-0243-7
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1365/s10337-004-0243-7